446292-08-6 Usage
Description
1H-ISOINDOLE-1,3(2H)-DIONE, 2-[[(5S)-2-OXO-3-[4-(3-OXO-4-MORPHOLINYL)PHENYL]-5-OXAZOLIDINYL]METHYL]is a complex organic compound characterized by its unique molecular structure. It is a white solid and serves as a crucial intermediate in the synthesis of various pharmaceutical compounds, particularly rivaroxaban.
Uses
Used in Pharmaceutical Industry:
1H-ISOINDOLE-1,3(2H)-DIONE, 2-[[(5S)-2-OXO-3-[4-(3-OXO-4-MORPHOLINYL)PHENYL]-5-OXAZOLIDINYL]METHYL]is used as a key intermediate in the synthesis of rivaroxaban, an anticoagulant medication. Rivaroxaban is the first orally active direct factor Xa inhibitor, which plays a significant role in the coagulation cascade and is essential for the prevention and treatment of blood clot-related disorders.
Used as Rivaroxaban Intermediate:
1H-ISOINDOLE-1,3(2H)-DIONE, 2-[[(5S)-2-OXO-3-[4-(3-OXO-4-MORPHOLINYL)PHENYL]-5-OXAZOLIDINYL]METHYL]is specifically utilized in the production of rivaroxaban, which is a vital drug in the prevention and treatment of various blood clot-related conditions, such as deep vein thrombosis, pulmonary embolism, and stroke. Its role as an intermediate in the synthesis of rivaroxaban highlights its importance in the pharmaceutical industry and its contribution to the development of life-saving medications.
Flammability and Explosibility
Nonflammable
Check Digit Verification of cas no
The CAS Registry Mumber 446292-08-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,4,6,2,9 and 2 respectively; the second part has 2 digits, 0 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 446292-08:
(8*4)+(7*4)+(6*6)+(5*2)+(4*9)+(3*2)+(2*0)+(1*8)=156
156 % 10 = 6
So 446292-08-6 is a valid CAS Registry Number.
InChI:InChI=1/C22H19N3O6/c26-19-13-30-10-9-23(19)14-5-7-15(8-6-14)24-11-16(31-22(24)29)12-25-20(27)17-3-1-2-4-18(17)21(25)28/h1-8,16H,9-13H2/t16-/m1/s1
446292-08-6Relevant articles and documents
Preparation method of rivaroxaban intermediate
-
Paragraph 0083-0105, (2020/05/02)
The invention provides a preparation method of a rivaroxaban intermediate. The preparation method comprises: (1) carrying out a reaction on a compound A and a compound B in an alcohol or an alcohol aqueous solution to obtain a compound C; and (2) reacting the compound C with N,N'-carbonyldiimidazole in a reaction solvent selected from acetonitrile or butyronitrile to obtain a reaction solution containing a compound D, and performing cooling crystallization to obtain a compound D.
Preparation method of rivaroxaban intermediate
-
, (2020/04/17)
The invention belongs to the field of drug synthesis, and relates to a preparation method of a rivaroxaban intermediate. The rivaroxaban intermediate is further used for preparing rivaroxaban, and thesynthesis method has the advantages of simple operation, high product yield and high purity, and can meet the requirements of industrial production.
Identification and Synthesis of Impurities During a Novel Process Development of Rivaroxaban
Yu, Jun,Qiu, Peng-Cheng,Ke, Bin,Chen, Hui,Zhao, Chuan-Meng,Zhang, Fu-Li
supporting information, p. 2852 - 2858 (2018/10/26)
During the development of rivaroxaban, seven process-related impurities have been identified and synthesized. These structures are confirmed by nuclear magnetic resonance spectroscopy and high-resolution mass spectrometry. The impurities (S)-2-(2-((4-(5-(aminomethyl)-2-oxooxazolidin-3-yl)phenyl)amino)ethoxy)acetohydrazide (A) and (S)-4-(4-(((2-oxooxazolidin-5-yl)methyl)amino)phenyl)morpholin-3-one (F) are confirmed and distinguished from their isomers by single-crystal diffraction. This work proves to be valuable in regard to complying with regulatory norms and assessing the quality of rivaroxaban.
